Open AccessThe "antidementia drug", pantoly-GABA, increases choline acetyltransferase activity in mouse brain.
Author(s) -
Masanobu Nakahiro,
Isao Fukuchi,
Shuji Uchida,
Hiroshi Yoshida
Publication year - 1989
Publication title -
japanese journal of pharmacology/japanese journal of pharmacology
Language(s) - English
Resource type - Journals
eISSN - 1347-3506
pISSN - 0021-5198
DOI - 10.1254/jjp.49.407
Subject(s) - striatum , choline acetyltransferase , hippocampus , cerebral cortex , pharmacology , in vivo , choline , cortex (anatomy) , medicine , acetylcholinesterase , endocrinology , drug , chemistry , acetylcholine , biology , enzyme , neuroscience , dopamine , biochemistry , microbiology and biotechnology
Studies were made on the effects of in vivo administration of an "anti-dementia drug", pantoyl-GABA, on choline acetyltransferase (ChAT) activity in mouse brain. Male ICR mice were treated intraperitoneally with 500 mg/kg of pantoyl-GABA, once a day, for various periods. Then they were killed, and the ChAT activities of their cerebral cortex, hippocampus and striatum were measured. Results showed that ChAT activity increased significantly in the cerebral cortex and hippocampus from day 5 and 7, respectively, of treatment, but did not increase in the striatum even after treatment for 14 days. The kinetics of ChAT activity were investigated in tissues from the cerebral cortex and hippocampus of mice treated with the drug for 7 days. Drug-treatment increased the Vmax value, but did not affect the Km values for choline and acetyl-CoA. These results indicate that long-term treatment with pantoyl-GABA enhanced ChAT activity, without altering the affinity of the enzyme for either substrate.